View Older Stories View More Recent Stories

Jan 13, 2022 07:00AM TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
Jan 10, 2022 04:30PM Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development
Dec 23, 2021 07:00AM EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
Dec 16, 2021 09:58AM EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
Dec 15, 2021 01:30AM Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Dec 12, 2021 10:00AM CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
Dec 9, 2021 10:09AM AstraZeneca (AZN) Announces ENHERTU Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
Dec 9, 2021 10:05AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
Dec 8, 2021 07:37PM EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
Dec 3, 2021 07:00AM AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
Dec 3, 2021 07:00AM AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
Nov 30, 2021 06:32AM AstraZeneca (AZN) Announces LYNPARZA Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
Nov 30, 2021 06:30AM LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
Nov 25, 2021 06:00AM Inaugural Asia Summit on Global Health successfully explores healthcare landscape
Nov 24, 2021 04:00AM Inaugural Asia Summit on Global Health opens today
Nov 18, 2021 07:15AM AstraZeneca (AZN) Announces New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
Nov 18, 2021 07:00AM New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
Nov 17, 2021 10:03AM AstraZeneca's (AZN) LOKELMA Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
Nov 17, 2021 10:03AM LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
Nov 17, 2021 04:00AM Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
Nov 5, 2021 07:00AM AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
Nov 2, 2021 07:00AM SAGA Diagnostics enters into an assay development agreement with AstraZeneca
Nov 1, 2021 11:08AM SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
Nov 1, 2021 07:00AM AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
Oct 25, 2021 04:21PM IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
Oct 20, 2021 09:00AM AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
Oct 15, 2021 07:00AM IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
Oct 8, 2021 07:01AM AstraZeneca's (AZN) Tezepelumab Granted Orphan Drug Designation for Eosinophilic Esophagitis
Oct 8, 2021 07:00AM Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
Oct 5, 2021 07:02AM AstraZeneca (AZN) Announces AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
Oct 5, 2021 07:00AM AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
Oct 4, 2021 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regim
Sep 29, 2021 07:00AM AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
Sep 27, 2021 07:00AM AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
Sep 24, 2021 06:46AM AstraZeneca (AZN) announces LYNPARZA in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line mCRPC
Sep 24, 2021 06:45AM LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
Sep 19, 2021 06:14PM AstraZeneca's (AZN) IMFINZI Plus Chemotherapy Tripled 3-Year Patient Survival in the CASPIAN Phase III Trial
Sep 18, 2021 11:30AM IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
Sep 18, 2021 11:30AM IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
Sep 18, 2021 09:05AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Sep 18, 2021 07:30AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
Sep 17, 2021 12:07PM AstraZeneca (AZN) Announces ENHERTU demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
Sep 17, 2021 12:05PM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
Sep 17, 2021 07:34AM AstraZeneca (AZN) Announces IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
Sep 17, 2021 07:30AM IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
Sep 9, 2021 11:00AM IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
Sep 9, 2021 07:00AM Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
Aug 31, 2021 07:00AM FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
Aug 20, 2021 07:00AM AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
Aug 9, 2021 09:17AM AstraZeneca (AZN) announces ENHERTU significantly improved PFS in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
View More Recent Stories View Older Stories